This study was just released regarding a new cancer protocol:Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol - ISOM cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/
Summary:
The article, written by Ilyes Baghli and co-authors, proposes a hybrid orthomolecular protocol targeting cancer through the mitochondrial-stem cell connection (MSCC) theory. The protocol combines orthomolecular treatments, such as high-dose vitamin C, vitamin D, zinc, and repurposed drugs like ivermectin and benzimidazoles. These are recommended to enhance oxidative phosphorylation (OxPhos), inhibit cancer fuels like glucose and glutamine, and target cancer stem cells (CSCs). Dosing is based on clinical studies, such as 10g of vitamin C intravenously.
In the article, the recommended dosing for ivermectin is 12 mg, taken every other day.
For fenbendazole (e.g. here), the suggested dose is 222 mg, taken daily. Both are part of the protocol to target cancer stem cells by inhibiting key pathways.
The recommended duration for both ivermectin (12 mg every other day) and fenbendazole (222 mg daily) in the protocol is 6 to 8 weeks, according to the article. After this period, further adjustments or continuations might depend on the individual case.
Vitamin C: 10 g, given intravenously 2-3 times per week.
This study was just released regarding a new cancer protocol:Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol - ISOM cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/
Summary:
The article, written by Ilyes Baghli and co-authors, proposes a hybrid orthomolecular protocol targeting cancer through the mitochondrial-stem cell connection (MSCC) theory. The protocol combines orthomolecular treatments, such as high-dose vitamin C, vitamin D, zinc, and repurposed drugs like ivermectin and benzimidazoles. These are recommended to enhance oxidative phosphorylation (OxPhos), inhibit cancer fuels like glucose and glutamine, and target cancer stem cells (CSCs). Dosing is based on clinical studies, such as 10g of vitamin C intravenously.
In the article, the recommended dosing forivermectin is 12 mg, taken every other day.
For fenbendazole, the suggested dose is 222 mg, taken daily. Both are part of the protocol to target cancer stem cells by inhibiting key pathways.
The recommended duration for both ivermectin (12 mg every other day) and fenbendazole (222 mg daily) in the protocol is 6 to 8 weeks, according to the article. After this period, further adjustments or continuations might depend on the individual case.
Vitamin C: 10 g, given intravenously 2-3 times per week.
Currently, reliable sources of Fenbendazole include: - SanareLab. Fenbendazole seems to have a wide dose range of efficacy, anywhere from 222mg a day to 2000mg a day. Joe Tippens cured his Stage 4 small cell lung cancer with 222mg. There are testimonials at 444mg where a Stanford Medicine Research Group published three Stage 4 Cancer cures at 1000mg (3 days a week). Cancer response to Fenbendazole is dose dependent. While some cancer types will be more sensitive to Fenbendazole than others, there is also the issue of the quality and fidelity of the product itself.Cancer response to Fenbendazole is dose dependent. While some cancer types will be more sensitive to Fenbendazole than others, there is also the issue of the quality and fidelity of the product itself.
